Highlights
- Second quarter operating expenses were USD 12,766 thousand against USD 21,276 thousand.
- The second quarter net loss was USD 8,328 thousand, or USD 0.12 per share.
- Cash and cash equivalents were USD 34,824 thousand at June 30, 2026.
- Management expects cash to fund operations into the second quarter of 2027.
Biomea Fusion, Inc. (NASDAQ:BMEA) shares were trading near their all-time low at USD 0.5562 on November 6, 2026, down 5.31% on the day. The clinical-stage company reported second quarter operating expenses of USD 12,766 thousand and a net loss of USD 8,328 thousand, or USD 0.12 per share.
Biomea develops novel small molecule therapies for metabolic diseases, with a focus on diabetes and obesity. Its approach uses covalent small molecules, which are synthetic compounds that form a permanent bond to a target protein.
Spending and Loss
Total operating expenses were USD 12,766 thousand against USD 21,276 thousand in the second quarter of 2025, and USD 25,540 thousand for the six months against USD 50,988 thousand. The loss from operations equaled those amounts.
The net loss was USD 8,328 thousand, or USD 0.12 per share, against USD 0.51 per share a year earlier. For the six months, the loss per share was USD 0.29 against USD 1.29, and the accumulated Deficit moved to USD 469,791 thousand from USD 449,048 thousand at December 31, 2025.
General and administrative expenses decreased by USD 1.1 million in the quarter and USD 4.2 million for the six months. The filing describes decreases of USD 0.9 million and USD 2.7 million in personnel-related expenses, including stock-based compensation.
Cash and Runway
Cash and cash equivalents were USD 34,824 thousand against USD 55,812 thousand at December 31, 2025. Cash, cash equivalents and restricted cash were USD 35.2 million. Net cash used in Operating Activities was USD 21,697 thousand for the six months against USD 44,879 thousand.
The filing states that current resources are sufficient to fund operations into the second quarter of 2027, and that the ability to continue as a Going Concern will require additional financing. It adds that there is no assurance such financing will be available.
Financing History
Net cash provided by financing activities was USD 0.2 million during the six months ended June 30, 2026. In the same period of 2025 it was USD 42.8 million.
Balance Sheet
Total Assets were USD 36,873 thousand against USD 58,572 thousand. Total liabilities were USD 24,736 thousand against USD 29,020 thousand, and total stockholders' Equity was USD 12,137 thousand against USD 29,552 thousand. The company had 72,483,852 shares outstanding as of July 31, 2026.






Please wait processing your request...